CS/CS/HB 7095 - Prescription Drugs Summary

• Controlled Substance Prescribing Standards: Requires physicians prescribing controlled substances for chronic nonmalignant pain to register as "controlled substance prescribing practitioners" and comply with mandatory standards including physical examinations, written treatment plans, patient agreements, and regular monitoring for substance abuse.

• Counterfeit-Resistant Prescription Pads: Mandates that all controlled substance prescriptions be written on counterfeit-resistant pads from approved vendors or electronically prescribed, with vendors required to submit monthly reports documenting prescription pad sales.

• Pain Management Clinic Regulations: Expands oversight of pain-management clinics through registration requirements, facility standards, infection control protocols, quality assurance programs, and quarterly reporting; adds exemptions for clinics owned by board-certified specialists in anesthesiology, physiatry, or neurology.

• Pharmacy Permit and Reporting Requirements: Implements stricter pharmacy permit applications including criminal background checks, disclosure of financial interests, and written policies for preventing fraudulent controlled substance dispensing; requires pharmacists to report fraudulent obtaining of controlled substances to law enforcement within 24 hours.

• Prescription Drug Monitoring Program: Accelerates reporting requirements from 15 to 7 days, requires criminal background screening for database access, restricts manufacturer funding, and establishes authority for Department of Health to monitor suspicious purchasing patterns of controlled substances.